CHICAGO -- The targeted agent crizotinib (Xalkori) appears to dramatically reduce the size of tumors in children with refractory cancers that appear driven by the anaplastic lymphoma kinase (ALK), researchers reported.
CHICAGO -- A well-known anti-psychotic drug can help cancer patients bear some of the side effects of chemotherapy, a researcher said.
The novel diabetes drug dapagliflozin is set for approval in Europe, as is a new treatment for myelofibrosis. Also this week: Crime does not pay for Merck.
Fewer cycles of an intensive chemotherapy regimen for advanced Hodgkin's lymphoma improves outcomes and reduces toxicity, researchers found.
You’re just a "tweet" away. Follow us on Twitter to receive news and helpful updates throughout the day.
Sharing information with friends and family is the number one reason for social media outlets. Check out our Facebook page and become a fan!